AKAO 2018 Proxy Statement

43 The following table shows the payments that would be made to our NEOs assuming a qualifying termination or a qualifying termination following a change in control occurred on December 31, 2017. For Dr. Friedland, the table shows amounts actually paid, or accrued, under his separation agreement with the Company as of December 31, 2017. Name Cash Severance ($) COBRA Premiums ($) Equity Acceleration ($) (1) Other Payments ($) Total Potential Payment ($) (2) Kenneth J. Hillan, M.B., Ch.B. Qualifying Termination 452,400 22,932 364,812 840,144 Qualifying Termination in Connection with a CIC 904,800 34,398 959,998 1,899,196 Blake Wise Qualifying Termination 450,000 21,348 341,898 813,246 Qualifying Termination in Connection with a CIC 765,000 26,685 736,677 1,528,362 Tobin C. Schilke Qualifying Termination 273,750 16,011 211,413 501,174 Qualifying Termination in Connection with a CIC 492,750 21,348 718,658 1,232,756 Lee Swem, Ph.D. Qualifying Termination 240,000 7,875 115,069 362,944 Qualifying Termination in Connection with a CIC 432,000 10,500 359,415 801,915 Gary Loeb Qualifying Termination 270,000 16,011 62,843 348,854 Qualifying Termination in Connection with a CIC 486,000 21,348 341,050 848,398 Ian Friedland, M.D. Termination 319,800 5,697 656,988 (4) 346,905 (3) 1,329,390 (1) With respect to options, the value of equity acceleration was calculated by (i) multiplying the number of accelerated shares of common stock underlying the unvested, in-the-money options by $10.74, the closing stock price of our common stock on December 29, 2017, the last trading day of fiscal 2017 and (ii) subtracting the exercise price for the unvested stock options. With respect to RSUs, the value of equity acceleration was calculated by multiplying the number of accelerated RSUs by $10.74, the closing stock price of our common stock on December 29, 2017, the last trading day of fiscal 2017. (2) Amounts shown are the maximum potential payment the NEO would have received as of December 31, 2017. Amounts of any reduction pursuant to the 280G best pay provision, if any, would be calculated upon actual termination of employment. (3) Amounts include consulting fees paid to Planet Pharma, LLC and Friedland Strategic Consulting, LLC for Dr. Friedland’s services to the Company. (4) With respect to options, the value of equity acceleration was calculated by (i) multiplying the number of accelerated shares of common stock underlying the unvested, in-the-money options by $22.40, the closing stock price of our common stock on March 15, 2017, the date of Dr. Friedland’s separation and (ii) subtracting the exercise price for the unvested stock options. With respect to restricted stock units, the value of equity acceleration was calculated by multiplying the number of accelerated restricted stock units by $22.40.